Inclusion Criteria:

        Histologically confirmed primary invasive carcinoma of the uterine cervix Previously
        untreated disease Any cell type Stage IB2, IIA, IIB, IIIA, IIIB, or IVA Para-aortic lymph
        nodes negative by radiologic evaluation or by biopsy if CT scan is suspicious for
        adenopathy No known metastases to scalene nodes or other organs outside the radiotherapy
        field Study enrollment within 8 weeks of diagnosis Performance status - GOG 0-2 Absolute
        neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Bilirubin no
        greater than 1.5 times normal SGOT no greater than 3 times normal Creatinine less than 2.0
        mg/dL No renal abnormalities (e.g., pelvic kidney, horseshoe kidney, or renal
        transplantation) that would require modification of radiotherapy fields No bilateral
        ureteral obstruction allowed unless treated with stent or nephrostomy tube Not pregnant
        Fertile patients must use effective contraception No septicemia or severe infection No
        circumstance that would preclude study completion or follow-up No other malignancy within
        the past 5 years except nonmelanoma skin cancer No prior cytotoxic chemotherapy No prior
        pelvic or abdominal radiotherapy No prior therapy for this malignancy

        Exclusion Criteria:

        Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this
        study due to risks of fetal and teratogenic adverse events.(Note: Serum Pregnancy tests
        must be obtained in women of child bearing potential). Sexually active females may not
        participate unless they have agreed to use an effective contraceptive method (such as
        abstinence, diaphragm, condom, or intrauterine device) to prevent pregnancy for the
        duration of the study.

        Growth factor(s): Growth factors that support platelet or white cell number or function
        must not have been administered within the past 28 days.

        Erythropoietic drug(s): Erythropoietin or related hormones must not have been administered
        within the past 28 days.

        Infection: Patients who have an uncontrolled infection. Evidence of distant metastases
        Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a
        minimum of 3 years.

        Prior systemic chemotherapy within the last three years. Prior radiotherapy to the pelvis